Subeq [27] reported that intravenous administration of 3 mg/kg/day valsartan ameliorated chlorhexidine digluconate-induced peritoneal fibrosis by decreasing serum and dialysate TGF-β1 levels and significantly decreased the expression of TGF-β1, α-SMA, fibronectin, collagen and VEGF in rats’ peritoneum. This evidence concerns the gene ACTA1 and Peritoneal Fibrosis.